Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 80/100

Failure Rate

30.0%

3 terminated/withdrawn out of 10 trials

Success Rate

70.0%

-16.5% vs industry average

Late-Stage Pipeline

30%

3 trials in Phase 3/4

Results Transparency

0 of 7 completed trials have results

Key Signals

Enrollment Performance

Analytics

Phase 2

4(40.0%)

Phase 3

3(30.0%)

Phase 1

2(20.0%)

Early Phase 1

1(10.0%)

10Total

Phase 2(4)

Phase 3(3)

Phase 1(2)

Early Phase 1(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (10)

Showing 10 of 10 trials

NCT00216294Phase 2Completed

Safety Study of the Drug RG1068 in Patients With Obsessive Compulsive Disorder

Role: collaborator

NCT01371240Early Phase 1Withdrawn

Secretin-Assisted Computed Tomography Scan and Magnetic Resonance Imaging in Improving Pancreatic Tumor Conspicuity

Role: collaborator

NCT00076934Phase 1Completed

Safety of RG2077 in Patients With Multiple Sclerosis

Role: collaborator

NCT00235274Phase 2Completed

Effects of RG1068 (Secretin) on Information Processing in Schizophrenia

Role: collaborator

NCT00812058Phase 2Completed

A Study to Assess the Safety, Tolerability and Efficacy of RG2417 in Bipolar I Depression

Role: lead

NCT00660335Phase 3Completed

Safety and Efficacy of Synthetic Human Secretin-Enhanced MRCP in Subjects With Abnormalities of the Pancreas

Role: lead

NCT00322764Phase 2Completed

Phase II Study to Assess RG2417 in the Treatment of Bipolar I Depression

Role: lead

NCT00036231Phase 3Terminated

Synthetic Human Secretin in Children With Autism and Gastrointestinal Dysfunction

Role: lead

NCT00060515Phase 1Terminated

RG2133 (2',3',5'-Tri-O-Acetyluridine) in Mitochondrial Disease

Role: lead

NCT00036244Phase 3Completed

Synthetic Human Secretin in Children With Autism

Role: lead

All 10 trials loaded